David Rolfe’s Abiomed Inc ABMD Stock Holding History

David Rolfe’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,000	Closed	-$260K	–	40
2019 Q2	$260K	Buy	+1,000	New	+$265K	0.02%	37

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

David Rolfe's ABMD Position: Q3 2019 in Review

David Rolfe sold out of Abiomed Inc (ABMD) in Q3 2019, closing a stake of 1,000 shares — an estimated $260K sold.

David Rolfe first reported a position in ABMD in Q2 2019 and held it in 1 quarter. The position peaked at $260K in Q2 2019. 443 funds tracked by Wall St. Rank hold ABMD as of Q3 2019.

David Rolfe reported no remaining Abiomed Inc position as of Q3 2019 after selling out during the quarter.
David Rolfe sold 1,000 Abiomed Inc shares in Q3 2019, an estimated $260K.
David Rolfe first reported a position in Abiomed Inc in Q2 2019 and held it in 1 quarter.
David Rolfe's Abiomed Inc position peaked at $260K in Q2 2019.
443 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2019.

Based on Wedgewood Partners's 13F filing for Q3 2019, filed 14 Nov 2019.